No Abstract Available.
Humans ; Kidney Failure, Chronic* ; Rupture* ; Tendons*

The uterine cervical cancer is the rnost common tumor of malignant gynecologic tumors and complete remission of the cancer has been possible through early diagnosis and treatment. To evaluate the efficacy of tumor markers SCCA and CEA in patients with uterine cervical cancer as markers for monitoring, we analyzed serum SCCA and CEA crncentrations of 43 patients wit.h uterine cervical caner as a study group and 73 patients with benign pelvic disease as a contrnl group, were admitted to depar tment of Obstetncs & Gynecology, College of Medicine, Kyung Hee University from May 1991 to January 1993. The results were as follows ; 1. The distrihution of the clinical stages of 43 cervical cancers were : CIS 9, stage I 11, stage II 12, stageg III 5, stage lV 6. 2. The positive rate of SCCA of control group was 17%, and that of CEA nf control group was 12%. And the positive rate of SCCA of study group was 46.5% and that of CEA of study was 27.9%. 3. The average concentration of SCCA of control group was 0.71ng/ml and that of SCCA of study group was 8.25ng/ml(p<0.05). 4. The average concentration of CEA of control group was 1.95ng/ml and that of CEA of study group was 8.33ng/ml(p<.0.05). 5. The average concentration of SCCA by stage were 1.15ng/rnl for C1S, 1.14ng/ml for stage I, 9.72ng/rnl for stage III, 16.75ng/rnl for stage III, 21.95ng/ml for stage IV. Here, the mean value of SCCA was increased stepwise through cliinical stage, there was a correlation between the clinical stage and the concen tration of serum SCCA (p>0.05). 6.The average concentration of CEA by stage were 3.11ng/ml for CIS, 1.96ng/ml for stage I, 8.11ng/rnl for stage II, 18.92ng/ml for stage III, 19.44ng/ml for stage IV. There was not a correlation between the clinical stage and the concentration of serm CEA. 7. When the cervical cancer was divided by histologic subtypes, the average concentration of SCCA in squamous cell carcinoma of uterine cervix was 11.86ng/ml and the positive rate of SCCA in squamous cell carcinoma was 53.6%(9.46ng/ml & 58.8% in large keratinizing cell type, 15.56ng/ml & 45.5% in large nonkeratinizing cell type). And the average concentration of SCCA in adenocarcinoma was 1.32ng/ml positive rate was 40.0%. The tumor marker SCCA was more sensitive to squamous cell carcinoma rather than adenocarcinoma. 8. The sensitivities of SCCA in preinvasive cancer and invasive cancer were 22.2% and 52.9%, respectively. The average concentration of SCCA in invasive cancer was 10.04ng/ml and was more significantly elevated than of SCCA in preinvasive cancer. 9. Using SCCA & CEA together as markers for monitoring, the positive rate significantly incresaed to 70.6%(p<0.05). But measuring the two tumor marker alone, that not significantly increased. 10) . The diagnostic efficacy of SCCA in cervical cancer was 59.0%, that was higher as compaired with that of CEA. These results suggest that the serum concentration of SCCA is significantly increased stepwise by clinical stage and concomitant measurements of serum SCCA & CEA are more useful in diagnosis of cervical cancer. However measurements of SCCA and/or CEA have little efficacy in the detection of early cervical cancer considering it's low rate of positivity in early cervical cancer. We will evaluate the efficacy of two tumor markers in determining prognosis, therapeutic response and early detection of recurrence for the posttreatment patients in the future.
Adenocarcinoma ; Carcinoma, Squamous Cell ; Cervix Uteri ; Diagnosis ; Early Diagnosis ; Female ; Gynecology ; Humans ; Prognosis ; Recurrence ; Selective Estrogen Receptor Modulators ; Biomarkers, Tumor* ; Uterine Cervical Neoplasms*

No abstract available.
Animals ; Nerve Regeneration* ; Rats* ; Sciatic Nerve*

Though congitive functions of a man decline in normal aging and memory decline is the most common complaint of an elderly, the status of quantitive and qualitative estimates of these are rare in Korea. To assess the qualitative and quantitive aspect of changes of memory in aging, neuropsychological tests about memory functions were performed and the results were.analyzed in healthy adult volunteers of 20 to 9 year-old, having no evidence-of organic brain dysfunction. The scores of each tests.are lower than that of English-speaking countries, but memory functions declined significantly in normal aging and the qualitative aspect of these are characteristics. Contrary to the western reports. The visuospatial memory declined significantly before the age of 50 and the verbal memory after 50 in aging. So we should take care in screening and diagnosis of dementia and amnesia using these neuropsychological test in Korea.
Adult* ; Aged ; Aging* ; Amnesia ; Brain ; Child ; Dementia ; Diagnosis ; Humans ; Korea ; Mass Screening ; Memory* ; Neuropsychological Tests ; Volunteers

Historically, gastrointestinal stroma tumors (GIST) have been considered as smooth muscle tumors, but the controversy over this histogenesis is provoked due to various results with utilizing immunohistochemical methods. In andeffort to further clarify the histogenesis of GIST, we performed the immunohistochemical study, as well as histopathologic reexamination, of 24 cases, all diagnosed as smooth muscle tumors of gastrointestinal tract, from Seoul Paik Hospital and Ewha University Hospital between 1980 and 1989, and the main results were as follows; 1) In the histopathologic features by light microscopic study, 11 benign and 13 malignant lesions (including one high grade malignancy and 12 low-grade malignant lesions) were disclosed. 2) In the immunohistochemical study, all tumors showed Vimentin positivity (100%), but no tumor showed S-100 protein positivity (0%), and 7 cases (29.1%) showed Desmin positivity. Positive reaction for Desmin made it possible to suggest that the histogenesis of GIST be in smooth muscle, and neurogenic origin would be excluded by all negativity for S-100 protein. In summary, we would like to conclude that GIST would be smooth muscle tumors on account of their morphological characteristics and their intramural location, but most of them appear poorly differentiated by immunohistochemical method.

The relative bioavailability amd palsma level fluctuation of controlled release carbamazepine (carbamazepine CR, CBZ CR, Tegretol CR) to the regular product (Carbamazepine RR, CBZ RR, Tegletol RR) were studied in 12 patients who were taking stable dose of carbamazepine for more than six weeks. Fixed dosage regimen (400 mg every 12 hours) of both products was administered in a random cross over manner at least for four days. After reaching steady-state, serial blood samples were drawn after last dose administration. Plasma carbamazepine levels were analysed by fluorescence polarizing immunoassay. The controlled lelease products showed lower area under the concentration time curve (AUC; 89.7)20.0 ug/ml/hr) than that (107.1)13.2 ug/ml/hr) of the regular products (p<0.01), and also showed low peak plasma level (CR;848)l.93ug/ml, RR;10.57+1.55 ug/ml). However. Fluctuation of plasma drug level during dose interval was slightly less in controlled release products compared with carbamazepine regular products in the respect of various indices such as percent fluctuation, fluctuation index and area deviation from mean level. However those parameters did not show no statistical singificance between two products except area diviation (p<0.01). Though the controlled relase product showed slightly less fluctuation during dose interval, this seemed to be the expense of incomplete bioavailability. As a conclusion, the dose correction should be made according to the relative bioavailability of controlled release formulation if switching of the formulation from regular to controlled release form would be needed. However it could not be proved that controlled release fromulation had less fluctiuation during dose interval in this study. More detailed studies should be pursued to show the evidence of significant superiority of currently marketing controlled release formulation to the regular one.
Biological Availability* ; Carbamazepine* ; Fluorescence ; Humans ; Immunoassay ; Marketing ; Plasma

No abstract available.
Hemoptysis*

No abstract available.
Female ; Pregnancy ; Pregnancy, Ectopic*

No abstract available.
Child* ; Humans ; Infant* ; Intussusception*